Drospirenone with 17β-estradiol in the postmenopausal woman with hypertension

@article{White2007DrospirenoneW1,
  title={Drospirenone with 17$\beta$-estradiol in the postmenopausal woman with hypertension},
  author={William B. White},
  journal={Climacteric},
  year={2007},
  volume={10},
  pages={25 - 31}
}
  • W. White
  • Published 1 January 2007
  • Medicine, Biology
  • Climacteric
Hypertension is one of the most important risk factors for the development of cardiovascular disease. The prevalence of hypertension increases with age and also after the menopause; therefore, blood pressure monitoring and effective control of elevated blood pressure are very important in postmenopausal women. The knowledge that aldosterone is a dual cardiovascular and endocrine hormone has blurred the once distinct boundary between gynecology and cardiovascular medicine. Aldosterone plays a… 
View on Taylor & Francis
ncbi.nlm.nih.gov
21 Citations
Background Citations
3
Methods Citations
3

21 Citations

Cardiovascular Risk During the Menopause

Although initial experimental data and results of observational studies suggest that hormone replacement (HRT) is associated with a reduction in the risk of heart disease, the results for events such as stroke or thromboem- bolism are less clear, HRT therapy should not be initiated to prevent vascular disease among postmenopausal women.

Sex differences and central protective effect of 17beta-estradiol in the development of aldosterone/NaCl-induced hypertension.

The results indicate that central estrogen plays a protective role in the development of Aldo/NaCl-induced hypertension and that this may result from reduced sympathetic outflow.

Progestogens and target tissues: vascular systems.

Clinical experiences with drospirenone: from reproductive to postmenopausal years.

Effect of aerobic exercise on blood lipid levels in postmenopausal women

The results of this study showed that all four lipid levels differed significantly between the control group and the intervention group, the respective mean levels ± SD for TC being 228.0 ± 39.7 mg/dL vs. 171.6 ± 18.4mg/dL, p = 0.000; and practitioners recommending exercise for coronary artery disease risk reduction in postmenopausal women.

Characteristics of nasal epithelial cells in naturally postmenopausal women receiving hormone therapy with 1 mg 17&bgr;-estradiol and 2 mg drospirenone: a prospective study

The study confirmed that the nasal respiratory epithelium is an ovarian steroid target and Drospirenone acts on nasal cells similarly to other progestogens.

Climacteric Commentaries

Commentary on sex steroids being made intracellularly in peripheral tissues by the mechanism of intracrinology after menopause and a calcium-collagen chelate dietary supplement for attenuation of bone loss in postmenopausal women with osteopenia.

Prospective study evaluating olfactometric and rhinomanometric outcomes in postmenopausal women on 1 mg 17&bgr;-estradiol and 2 mg drospirenone HT

It is confirmed that the nasal airflow resistance and olfactory thresholds to odors may depend on steroid hormones, and it is believed that estrogens could influence neuronal plasticity and the neuronal conduction time in the Olfactory system.

Bioidentical Hormones: An Evidence-Based Review for Primary Care Providers

  • E. Conaway
  • Medicine, Biology
    The Journal of the American Osteopathic Association
  • 2011
Bioidentical hormones that are approved by the FDA may be preferred over standard hormone replacement because of their physiologic benefits and safety profile.

Preventing recurrent venous thromboembolism

The evidence regarding risk factors for recurrence that might influence the decision to recommend prolonged anticoagulant therapy after a first episode of venous thromboembolism is reviewed, and the implications for practice are considered.

References

SHOWING 1-10 OF 36 REFERENCES

Effects of a New Hormone Therapy, Drospirenone and 17-&bgr;-Estradiol, in Postmenopausal Women With Hypertension

Data show that DRSP combined with E2 significantly reduces BP in postmenopausal women with hypertension and did not induce significant increases in serum potassium, which may lead to a new benefit for this novel hormone therapy in postwomen's hypertension.

Antihypertensive Effects of Drospirenone With 17&bgr;-Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 Hypertension

Combination therapy with DRSP/E2 significantly lowered both clinic and 24-hour systolic BP in postmenopausal women with stage 1 systolics hypertension, which may lead to benefit for cardiovascular risk reduction in this population of women.

Interactions of High Salt Intake and the Response of the Cardiovascular System to Aldosterone

  • P. Conlin
  • Biology, Medicine
    Cardiology in review
  • 2005
Aldosterone blockade with mineralocorticoid receptor antagonists offers target organ protection and may blunt some of the adverse effects of chronic high salt intake.

Conception and pharmacodynamic profile of drospirenone

Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.

  • E. Mcmahon
  • Biology, Medicine
    Current opinion in pharmacology
  • 2001

Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.

Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.

Antialdosterones: incidence and prevention of sexual side effects.

The influence of menopause on blood pressure.

In the present cross-sectional study menopause was accompanied by a steeper rise of SBP with age, and by an increase in the absolute level of DBP, which was independent of age.

Drospirenone: a Novel Progestogen with Antimineralocorticoid and Antiandrogenic Activity

Drospirenone exerts potent progestogenic and antigonadotropic activity which was studied in various animal species and efficiently promotes the maintenance of pregnancy in ovariectomized rats, inhibits ovulation in rats and mice and stimulates endometrial transformation in the rabbit.